A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP
← catalyst calendarSponsored by Monte Rosa Therapeutics, Inc (industry) · GLUE — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
100estimated
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-27 | actual | When the study began enrolling |
| Primary completion | Jul 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Healthy Volunteers
- Elevated CRP
Interventions
- Drug: MRT-8102
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFTo evaluate the safety and tolerability of single doses of MRT-8102 in healthy adult participants
measured 15 days
To evaluate the safety and tolerability of multiple ascending doses of MRT-8102 in healthy adult participants.
measured 21 days
To evaluate the safety and tolerability of 28-day daily dosing of MRT-8102 in participants at cardiovascular risk with elevated CRP
measured 56 days
Permalink · GLUE's whole pipeline · Catalyst calendar · Every registered study · What changed